Crossmark

A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells

Crossref DOI link: https://doi.org/10.1039/C8TB00546J

Published Online: 2018

Update policy: https://doi.org/10.1039/rsc_crossmark_policy

Authors

Hu, Mingxing

Yang, Chao

Luo, Yi

Chen, Fan

Yang, Fangfang

Yang, Shuping

Chen, Hao

Cheng, Zhiqiang https://orcid.org/0000-0002-4371-0104
Li, Kun https://orcid.org/0000-0002-8788-1036
Xie, Yongmei https://orcid.org/0000-0002-7913-0283
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (21232005)

National Natural Science Foundation of China (21572147)

National Natural Science Foundation of China (J1103315)
License Information

Accepted Manuscript valid from 2019-04-03
More Information

SIMILARITY CHECK

: This document is Similarity Check deposited

ASSOCIATED ARTICLES

CrossRef DOI Link to Correction:: https://doi.org/10.1039/C8TB90081G

RELATED DATA

: Supplementary Information

IDENTIFIERS

: Zhiqiang Cheng (ORCID)

: Zhiqiang Cheng (ResearcherID)

: Kun Li (ORCID)

: Yongmei Xie (ORCID)

PEER REVIEW METHOD

: Single-blind

PUBLICATION HISTORY

: Received 16 March 2018; Accepted 3 April 2018; Accepted Manuscript published 3 April 2018; Advance Article published 16 April 2018; Version of Record published 25 April 2018